Time to Thrombocytic Inhibition After Supine and Upright Ingestion of Efient
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 20
- 试验地点
- 2
- 主要终点
- Change in Inhibition of ADP-receptors on thrombocytes
研究概览
简要总结
The purpose of the study is to clarify wether body posture during ingestion of 60mg Efient, a thrombocytic inhibitor, has influence on the time to thrombocytic inhibition.
The study aims to mimic the treatment Danish patients receive when admitted to the hospital with a ST-elevation myocardial infarction since these patients are refereed to acute Percutaneous Coronary Intervention (PCI) necessitating fast and efficient thrombocytic inhibition.
Current guidelines recommend the administration of Efient right before the PCI procedure, while the patient is lying down, either in the ambulance or in the operating room. We, the investigators, believe that this is suboptimal for the patient, since any sort of prolonged inhibition time will possibly worsen the patients prognosis and make the patient more prone to later clotting issues.
Our hypothesis is that by making the patients ingest the tablets in a 90 degrees upright position and making them sit up for 2 minutes after ingestion, the effect of the pills will commence faster than if taken in a supine position. This will possibly lead to faster inhibition of the thrombocytes, which we believe will lead to a lower incidence of clotting issues during and after the procedure.
详细描述
The study will be divided into two sessions: first session will be the control arm- ingestion of Efient in supine position.
14 days later, the same test-persons will be doing the intervention- ingestion of Efient sitting upright for 2 minutes. Besides this, the second session will be exactly the same as the control arm.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 30 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •20-30 years of age
- •Ability to give informed consent
- •Non-Smoker
排除标准
- •Known with reflux or dysphagia
- •Ingestion of medicine, beside Paracetamol <14 prior to the trial
- •Hematological diseases
- •Known kidney disease
- •Known liver disease
- •Recent trauma
- •Scheduled operation within 7 days after the trial
- •Former apoplexia
- •Known gastro-intestinal disease
- •Weight <60 kg
研究组 & 干预措施
Standard administration of Efient
The test person will ingest Efient in supine position, and remain supine during 2 hours, mimicing the way Efient is used for pre-PCI treatment today
Upright administration of Efient
The test person will ingest Efient in an upright position, and remain supine during 2 hours.
干预措施: Upright position (Other)
结局指标
主要结局
Change in Inhibition of ADP-receptors on thrombocytes
时间窗: Blood will be drawn from the test person at 0, 20, 40, 60, 80, 100minutes post ingestion.
The primary outcome will be the difference between the time to sufficient/maximal inhibition of the ADP-receptors on the test-persons thrombocytes compared between supine and upright ingestion of Efient. Inhibition will be verified bedside by VerifyNow analyses.
次要结局
未报告次要终点
研究者
Jacob Antonsen
Medical Doctor
Rigshospitalet, Denmark